Purchase this article with an account.
Jennifer I Lim, Adam R Glassman, Lloyd P Aiello, Usha Chakravarthy, Christina J Flaxel, Lawrence J Singerman, Richard F Spaide; Macula Society Collaborative Retrospective Study of Ocriplasmin for Vitreomacular Traction. Invest. Ophthalmol. Vis. Sci. 201657(12):.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To assess anatomic and visual outcomes of ocriplasmin for treatment of vitreomacular traction (VMT).
Macula Society members were surveyed online to retrospectively collect data on patients receiving ocriplasmin for VMT. Clinical findings, optical coherence tomography (OCT) parameters, change in visual acuity, and adverse events were collected online using standardized forms.
There were 223 eyes (223 patients) with VMT. Macular hole (MH) was present at baseline in 79 eyes (35%); MH size was < 400 µ in 64 of 77 (83%) eyes with data available on hole size. VMT adherence was focal (<1500 µ) in 192 of 202 (95%) eyes with available data. Follow-up ranged from 1 day (1 eye) to 18 months. VMT resolved in 44% of eyes by 1 week, 50% of eyes by 1 month, 58% of eyes by 12 weeks and 74% of eyes at the final visit. Pars plana vitrectomy (PPVx) was performed in 6% by 1 month, 15% by 12 weeks and 29% by the last follow-up. MH closure without PPVx occurred in 16% by 1 week, 35% by 4 weeks, 40% at 12 weeks and 40% at the final visit. There was no association between rate of closure and hole size. Including PPVx, MH closure occurred in 67/79 eyes (85%) by the last visit. Mean change between baseline and final visual acuities was -0.14 logMAR;15% of eyes lost ≥ 2 lines and 39% gained ≥ 2 lines. Scleral buckling with PPVx was performed in 1 eye and cataract extraction in 10 eyes (4%). Complications included photopsias (35 eyes, 16%), dimness of vision (35 eyes, 16%), decreased color vision (23 eyes, 10%), MH development (11 eyes, 7.6%), macular RPE atrophy (6 eyes, 2.7%), retinal detachment (4 eyes, 1.8%) and retinal tear (2 eyes, 0.9%). Diminished ERG was found in 9 eyes, 8 of which had MH. No cases of endophthalmitis were reported.
Ocriplasmin results in release of VMT in 45% of eyes and closure of macular holes in 40% without PPVx with stable or improved visual acuity in 85% eyes. Adverse events were not infrequent but mostly not serious.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.
This PDF is available to Subscribers Only